Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
|Articles|January 31, 2014
The Distribution and Geographic Accessibility of Prostate Cancer Clinical Trials in the U.S.
Author(s)Matthew D. Galsky, MD
Matthew D. Galsky, MD, from The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.
Advertisement
Clinical Pearls
Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.
- Classically defined barriers to enrollment on clinical trials have been patient awareness, acceptance of enrollment, and eligibility of enrollment
- Much less work has been done on the availability of cancer clinical trials
- This analysis aimed to answer the question of how far would an individual would have to travel to access their closest clinical trial site
- A large proportion of the population would need to travel greater than 30 miles to reach a cancer clinical trial site
- Greater than 30 miles has been used to characterize ‘high travel burden’ in previous studies
<<<
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5